• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Cardlytics May Not Give Buyers a Dip to Buy in This Strong Market

Jim Cramer said he'd bless buying Cardlytics but only under $70 a share.
By BRUCE KAMICH
Feb 14, 2020 | 09:41 AM EST
Stocks quotes in this article: CDLX

In his "Homework" segment of Mad Money Thursday night, Jim Cramer followed up on a stock that had stumped him during earlier shows. He said that Cardlytics (CDLX) has a unique business model and tons of growth. Their recent deals with two banks are huge wins for the company, he admitted, but the stock has a big problem.

Shares of CDLX are up 173% in just the past six months and trade at an astronomical 107 times earnings. Given the company has small earnings, Cramer also considered valuing the company based on revenues. Using that metric, Cardlytics still trades for seven times revenue.

Cramer said he'd bless buying Cardlytics but only under $70 a share. The stock closed Thursday at $93.07. Let's check the charts if a pullback to $70 is in the cards.

In this daily bar chart of CDLX, below, we can see that shares of CDLX have made a big move higher the past 12 months. CDXL is up some five-fold in a year and has made someone's portfolio very happy.

Prices are above the rising 50-day moving average line and perhaps extended above the rising 200-day moving average line. The daily trading volume has been increasing since May and that is a positive for old chart watchers like myself.

The daily On-Balance-Volume (OBV) line has been in an uptrend the past year and tells us that buyers of CDLX have been more aggressive.

The 12-day price momentum study or indicator in the bottom panel of the chart shows the start of a bearish divergence. CDLX made a new high for the move up this month but the rate of the price gains has slowed. This is probably not enough of a bearish divergence to generate a correction but it is now on our watch list.

In this weekly bar chart of CDLX, below, we have a limited price history but the indicators are mostly bullish with a rising 40-week moving average line and a rising OBV line. The 12-week price momentum study shows that the pace of acceleration has started to slow.

In this Point and Figure chart of CDLX, below, we can see two key features. First, this chart shows a potential upside price target of $130. Second, a break below $81 will likely weaken the chart as it would break nearby support. While Jim Cramer likes CDLX on pullback to $70, I would not want to catch a falling knife.

Bottom line strategy: Analysts have different approaches to the market. Some want to buy a correction in a strong trend and others like to buy strength because you never know how far a stock will decline once it turns lower.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from buying individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Business Communications | Mad Money

More from Investing

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Stocks Are Well Off Early Lows, but There's Still Quite a Bit of Weakness

James "Rev Shark" DePorre
Jan 22, 2021 1:18 PM EST

There is still strong interest in stock picking which is the most positive thing about this market.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login